Langerhans-cell histiocytosis
Drug research and approvals for langerhans-cell histiocytosis: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 22, 2026, 55 studies of langerhans-cell histiocytosis are recruiting on ClinicalTrials.gov, and Health Canada has authorized 0 drug trials for it since 2013.
- Recruiting worldwide: 55
- Trials authorized in Canada: 0
- FDA orphan approvals: 0
- EU medicines: 0
- Hemophagocytic Lymphohistiocytosis After Allogeneic Stem Cell TransplantationNCT07905066 · Not reported · Peking University People's Hospital · starts Oct 19, 2026
- Establishing a National Egyptian HLH Registry (NEHR)NCT07800234 · Not reported · Ain Shams University · starts Mar 2, 2024
- Retinal Hyperspectral Imaging in Neurodegenerative DiseasesNCT07545473 · Not applicable · Center for Eye Research Australia · starts Oct 11, 2021
- Combination of Mitoxantrone Liposome and Etoposide, Dexamethasone, Pegaspargase and Golidocitinib (MEPL-G) in the…NCT07525466 · Phase 1 / Phase 2 · Beijing Tongren Hospital · starts Apr 1, 2026
- ECD-Score: a Study on Erdheim-Chester DiseaseNCT07454343 · Not reported · Meyer Children's Hospital IRCCS · starts Dec 23, 2024
- DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young…NCT07440290 · Phase 2 / Phase 3 · Cancer Research UK · starts Apr 1, 2026
- Modified LCH-III Regimen With or Without Luvometinib for Multisystem Pediatric Langerhans Cell HistiocytosisNCT07431060 · Not applicable · West China Second University Hospital · starts Feb 13, 2026
- Luvometinib in Pediatric SS-LCH With Special-site Single/Multifocal Bone LesionsNCT07371182 · Not applicable · West China Second University Hospital · starts Jun 19, 2026
- Prospective Single-Arm Clinical Trial of GO Regimen for HLH.NCT07339345 · Phase 2 / Phase 3 · Beijing Friendship Hospital · starts Jun 27, 2025
Phase 3 5
- CytarabineDNA inhibitor
- PrednisoneGlucocorticoid receptor agonist
- VinblastineTubulin inhibitor
- MercaptopurineAmidophosphoribosyltransferase inhibitor
- VincristineTubulin inhibitor
Phase 2 12 of 21
- MethotrexateDihydrofolate reductase inhibitor
- ClofarabineRibonucleoside-diphosphate reductase RR1 inhibitor
- CladribineDNA inhibitor
- CyclophosphamideDNA inhibitor
- BusulfanDNA inhibitor
- Fludarabine
- IndomethacinCyclooxygenase inhibitor
- Mycophenolate mofetilInosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor
- TacrolimusFK506-binding protein 1A inhibitor
- ThalidomideCRL4(CRBN) E3 ubiquitin ligase inhibitor
- RituximabB-lymphocyte antigen CD20 binding agent
- Human immunoglobulin gReplacement therapy, immunomodulatory effects
How its trials ended
67 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 11 whose ending is known, 18% met their primary endpoint, 18% missed it and 64% stopped early.
- Ongoing3045%
- Completed, result not reported1624%
- Status unknown1015%
- Stopped: other or unclear46%
- Stopped: enrollment or feasibility34%
- Met its primary endpoint23%
- Missed its primary endpoint23%
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA